Search

Displaying results 1821 - 1830 of 10000 in total
  1. Drug

    Influenza B virus B/Maryland/15/2016 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14591
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.25ml, SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.5ml
  2. Drug

    Iomeprol

    go.drugbank.com/drugs/DB11705
    ApprovedInvestigational

    [A265090,A265095] Iomeprol first appeared in the market in 1994 [A265095] and is currently used in various diagnostic processes involving x-ray imaging and computed tomography (CT) scans.[L52260]

    Synonyms: N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(N-METHYLGLYCOLAMIDO)ISOPHTHALAMIDE, 1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO)-2,4,6-TRIIODO-Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220]. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11044
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Medical Provider Single Use EZ Flu Shot Afluria 2016-2017, Medical Provider Single Use EZ Flu Shot Fluvirin 2016-2017
  5. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    It is found in foods for food enrichment or in supplements for the treatment of iron deficiency or iron deficiency anemia.

    Mixtures: SetonET-EC, PR Natal 430 ec
  6. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]

  7. Drug

    Penicillium italicum

    go.drugbank.com/drugs/DB10811
    Approved

    Penicillium italicum extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  8. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway. … [A256828] In clinical trials, imlunestrant has been investigated as monotherapy and in combination with other drugs in breast cancer patients.[A256828]

  9. Drug

    Poloxamer 188

    go.drugbank.com/drugs/DB11333
    Approved

    Composed of two hydrophilic side-chains attached to a hydrophobic center core [A27218], its average molecular weight is 8400 Daltons. … P188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].

    Categories: Compounds used in a research, industrial, or household setting
  10. Target

    DNA polymerase epsilon subunit 3

    go.drugbank.com/bio_entities/BE0003617
    TargetHumans

    Does not enhance nucleosome sliding activity of the ACF-5 ISWI chromatin remodeling complex (PubMed:14759371) … Accessory component of the DNA polymerase epsilon complex (PubMed:10801849). Participates in DNA repair and in chromosomal DNA replication (By similarity).

    Synonyms: Chromatin accessibility complex 17 kDa protein